Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial

International Journal of Obesity volume 30, pages 1138–1142 (2006)Cite this article

Abstract

Background and objective:

Atomoxetine is a potent central norepinephrine uptake inhibitor, currently marketed for treatment of attention-deficit/hyperactivity disorder (ADHD). With the understanding that noradrenergic agents could be useful in assisting obese individuals to lose weight, we conducted this preliminary study to evaluate short-term efficacy and safety of atomoxetine in obese adults.

Design:

At 12-week randomised, double-blind, placebo-controlled trial, conducted at Duke University Medical Centre, USA, from May 2004 to December 2004.

Participants:

A total of 30 obese women (mean (s.e.) body mass index of 36.1 (0.6) kg/m2).

Interventions:

Participants were randomly assigned to receive atomoxetine (n=15) or placebo (n=15). All participants were advised to follow a balanced hypocaloric diet (500 kcal/day deficit). Atomoxetine therapy was started at 25 mg/day orally, with gradual increase to 100 mg/day over 1 week. Placebo dosing was identical.

Measurements:

Body weight in kilograms was the primary outcome measure. Other measurements included waist circumference, blood pressure and heart rate, fasting plasma glucose and lipids, and depressive symptoms.

Results:

Last-observation-carried-forward analysis of the available data for participants who had completed at least one post-randomisation assessment, demonstrated that the atomoxetine group (n=12) lost more body weight over the 12-week period than the placebo (n=14) group (mean (s.e.) −3.6 (1.0) kg (−3.7% loss) vs 0.1 (0.4) kg (0.2% gain); F4,96=11.9; P<0.0001). Three participants in the atomoxetine group and none in the placebo group lost ⩾5% weight. Side effects were minimal.

Conclusion:

Atomoxetine demonstrated modest short-term weight loss efficacy relative to placebo in this preliminary study of obese women.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Goldstein DJ . Beneficial health effects of modest weight loss. Int J Obes 1992; 6: 397–415.

    Google Scholar 

  2. National Heart, Lung and Blood Institute, National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. National Institutes of Health: Bethesda, MD, September 1998. Publication 98-4083.

  3. Yanovski SN, Yanovski JA . Obesity. N Engl J Med 2002; 346: 591–602.

    Article  CAS  Google Scholar 

  4. Hoebel BG, Leibowitz SF . Brain monoamines in the regulation of self-stimulation, feeding and body weight. In: Weiner H, Hofer MA, Stunkard AJ (eds.) The Psychobiology of Human Eating Disorders.. Annals of the New York Academy of Sciences: New York, 1989. pp 307–320.

    Google Scholar 

  5. Schwartz MW, Baskin DG, Kaiyala KJ, Woods SC . Model for the regulation of energy balance and adiposity by the central nervous system. Am J Clin Nutr 1999; 69: 584–596.

    Article  CAS  Google Scholar 

  6. Product information brochure for Strattera capsules. Eli Lilly and Company, 2002.

  7. Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.

    Article  CAS  Google Scholar 

  8. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996; 53: 777–784.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported by a grant from Eli Lilly and Company to Dr Gadde.

Author information

Authors and Affiliations

  1. Obesity Clinical Trials Programme, Duke University Medical Centre, Durham, NC, USA

    K M Gadde, G M Yonish, H R Wagner II & M S Foust

  2. Department of Biostatistics and Clinical Nutrition Research Centre, University of Alabama at Birmingham, Birmingham, AL, USA

    D B Allison

Authors
  1. K M Gadde
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G M Yonish
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H R Wagner II
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M S Foust
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D B Allison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K M Gadde.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gadde, K., Yonish, G., Wagner, H. et al. Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Int J Obes 30, 1138–1142 (2006). https://doi.org/10.1038/sj.ijo.0803223

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803223

Keywords

This article is cited by

Search

Advanced search

Quick links